Cited 0 times in
Molecular characteristics of incidental lower-grade glioma for treatment decision-making
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문주형 | - |
dc.date.accessioned | 2023-11-07T07:24:55Z | - |
dc.date.available | 2023-11-07T07:24:55Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 0022-3085 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196412 | - |
dc.description.abstract | Objective: Several limitations are associated with the early diagnosis and treatment of incidental lower-grade glioma (iLGG), and due to its unknown molecular features, its management is categorized as either the "wait-and-see" strategy or immediate treatment. Therefore, in this study the authors explored iLGG's clinical and molecular landscape to improve its management. Methods: The authors retrospectively assessed the differences between the molecular and clinical characteristics of iLGG and symptomatic lower-grade glioma (sLGG) samples filtered based on symptom data corresponding to The Cancer Genome Atlas cohort with mutations. Thereafter, genomic and transcriptomic analysis was performed. Results: There was no significant difference between iLGG and sLGG with respect to mutation status; however, there was an increase in the interaction between major mutations in sLGG, depending on the histological subtype and the IDH1 mutation status. Furthermore, the IDH1 mutation characteristics corresponding to wild-type glioma were much more obvious in sLGG than in iLGG. Additionally, in sLGG, genes associated with malignancy, including cell proliferation-related, cell migration-related, epithelial-to-mesenchymal transition-related, and negative regulation of cell death-related genes, were significantly upregulated, and groups showing higher expression levels of these genes were associated with worse prognosis. Also, 8 of the 75 identified upregulated genes showed positive correlation with resistance to the drugs that are normally used for glioma treatment, including procarbazine, carmustine, vincristine, and temozolomide. Conclusions: The new insights regarding the different molecular features of iLGG and sLGG indicated that the immediate management of iLGG could result in better prognosis than the wait-and-see strategy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Association of Neurological Surgeons | - |
dc.relation.isPartOf | JOURNAL OF NEUROSURGERY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Brain Neoplasms* / pathology | - |
dc.subject.MESH | Carmustine | - |
dc.subject.MESH | Glioma* / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Isocitrate Dehydrogenase / genetics | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Molecular characteristics of incidental lower-grade glioma for treatment decision-making | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Jeongman Park | - |
dc.contributor.googleauthor | Jeongmin Sim | - |
dc.contributor.googleauthor | Juwon Ahn | - |
dc.contributor.googleauthor | Yu Jin Kim | - |
dc.contributor.googleauthor | Sojung Hwang | - |
dc.contributor.googleauthor | Kyunggi Cho | - |
dc.contributor.googleauthor | Da-Young Chang | - |
dc.contributor.googleauthor | Jin-Hwa Jung | - |
dc.contributor.googleauthor | Ju Hyung Moon | - |
dc.contributor.googleauthor | KyoungSu Sung | - |
dc.contributor.googleauthor | Jaejoon Lim | - |
dc.identifier.doi | 10.3171/2022.6.JNS22967. | - |
dc.contributor.localId | A01383 | - |
dc.relation.journalcode | J01636 | - |
dc.identifier.eissn | 1933-0693 | - |
dc.identifier.pmid | 35986732 | - |
dc.identifier.url | https://thejns.org/view/journals/j-neurosurg/138/3/article-p629.xml | - |
dc.subject.keyword | chemoresistance | - |
dc.subject.keyword | incidental lower-grade glioma | - |
dc.subject.keyword | mutation analysis | - |
dc.subject.keyword | oncology | - |
dc.subject.keyword | symptomatic lower-grade glioma | - |
dc.subject.keyword | transcriptomic analysis | - |
dc.contributor.alternativeName | Moon, Ju Hyung | - |
dc.contributor.affiliatedAuthor | 문주형 | - |
dc.citation.volume | 138 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 629 | - |
dc.citation.endPage | 638 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROSURGERY, Vol.138(3) : 629-638, 2023-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.